North America Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The North America gastrointestinal drugs market is projected to grow significantly, reaching an estimated US$ 43,362.58 million by 2031, up from US$ 24,104.40 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.6% from 2023 to 2031.

Executive Summary and Market Analysis

The gastrointestinal drugs market in North America is divided into three primary regions: the United States, Canada, and Mexico. Several factors are driving the growth of this market, including the rising incidence of gastrointestinal disorders linked to lifestyle changes, government initiatives aimed at the prevention and treatment of these diseases, a robust healthcare infrastructure, a thriving pharmaceutical sector, comprehensive reimbursement coverage, and the presence of major pharmaceutical companies.

Market Segmentation Analysis

The North America gastrointestinal drugs market can be analyzed through various segments, including drug class, application, route of administration, and distribution channel.

1. Drug Class: The market is categorized into several drug classes, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share, reflecting their growing importance in treating gastrointestinal conditions.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease, gastroenteritis, celiac disease, and others. The IBS segment held the largest share in 2023, indicating a significant demand for treatments targeting this condition.

3. Route of Administration: The gastrointestinal drugs market is divided into oral and parenteral routes of administration. The oral segment dominated the market in 2023, as oral medications are often preferred for their convenience and ease of use.

4. Distribution Channel: The distribution of gastrointestinal drugs is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies represented the largest share of the market in 2023, highlighting the critical role of hospitals in dispensing these medications.

Market Outlook

Recent years have seen a surge in the development of advanced treatments, particularly biologics, which are increasingly used for managing inflammatory diseases. Biologics have revolutionized the treatment landscape for inflammatory bowel diseases (IBD), and their success has encouraged their application in other gastrointestinal disorders. These drugs target specific elements of the immune system that contribute to disease, making them effective for conditions such as eosinophilic esophagitis, celiac disease, and autoimmune hepatitis.

Biologics, particularly anti-TNF agents, have been pivotal in managing ulcerative colitis and Crohn's disease. These agents, which include well-known medications like Humira, Simponi, and Remicade, work by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that promotes inflammation. The introduction of these biologics has significantly improved the management of IBD, with many patients achieving remission through their use. The FDA has approved numerous biologic drugs for IBD treatment, including Humira, Cimzia, Simponi, Tysabri, Remicade, Entyvio, and Stelara. Notably, Vedolizumab has emerged as a preferred second-line biologic for moderate to severe cases of Crohn's disease and ulcerative colitis.

In February 2024, Celltrion Healthcare's Remsima SC received approval from Health Canada for maintenance therapy in IBD, further illustrating the ongoing innovation in this field. The increasing prevalence of gastrointestinal diseases in developing countries is also driving the demand for new biologics, contributing to market growth.

Country Insights

Geographically, the North American gastrointestinal drugs market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. The rising prevalence of gastrointestinal diseases in the US is a significant factor driving demand for these drugs. Conditions such as Crohn's disease and ulcerative colitis are particularly prevalent, with approximately 70,000 new cases diagnosed annually, according to the Crohn's & Colitis Foundation of America. The overall prevalence of IBD has increased notably from 2011 to 2020, with estimates suggesting that around 2.4 million Americans are affected.

Increased funding for research and development in gastrointestinal diseases is expected to enhance the focus on novel treatment options. For instance, Crohn's disease research received US$ 90 million in funding in 2022, underscoring the commitment to advancing treatment options.

The US FDA's approval of new drugs is also anticipated to bolster market growth. For example, in May 2020, the FDA approved Qinlock for advanced gastrointestinal stromal tumors, and in May 2024, Strides Pharma received approval for a generic version of Sucralfate Oral Suspension for various gastrointestinal conditions.

Company Profiles

Key players in the North America gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Product Code: TIPRE00016278

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. North America Gastrointestinal Drugs Market Landscape

4.1 Overview
4.2 PEST Analysis

5. North America Gastrointestinal Drugs Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Cases of Gastrointestinal Diseases
- 5.1.2 Increasing Development of Biologics
5.2 Market Restraints
- 5.2.1 High Cost of Biologics
- 5.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
5.3 Market Opportunities
- 5.3.1 Strategic Initiatives by Companies
5.4 Future Trends
- 5.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
5.5 Impact of Drivers and Restraints:

6. Gastrointestinal Drugs Market - North America Analysis

6.1 North America Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

7. North America Gastrointestinal Drugs Market Analysis - by Drug Class

7.1 Biologics
- 7.1.1 Overview
- 7.1.2 Biologics: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
- 7.2.1 Overview
- 7.2.2 Antidiarrheal and Laxatives: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Acid Neutralizers
- 7.3.1 Overview
- 7.3.2 Acid Neutralizers: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Anti-inflammatory Drugs
- 7.4.1 Overview
- 7.4.2 Anti-inflammatory Drugs: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Antiemetic and Antinauseants
- 7.5.1 Overview
- 7.5.2 Antiemetic and Antinauseants: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Gastrointestinal Drugs Market Analysis - by Application

8.1 Irritable Bowel Syndrome
- 8.1.1 Overview
- 8.1.2 Irritable Bowel Syndrome: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
- 8.2.1 Overview
- 8.2.2 Inflammatory Ulcerative Colitis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Crohn's Disease
- 8.3.1 Overview
- 8.3.2 Crohn's Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Gastroenteritis
- 8.4.1 Overview
- 8.4.2 Gastroenteritis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Celiac Disease
- 8.5.1 Overview
- 8.5.2 Celiac Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Gastrointestinal Drugs Market Analysis - by Route of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Parenteral
- 9.2.1 Overview
- 9.2.2 Parenteral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Gastrointestinal Drugs Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Gastrointestinal Drugs Market - Country Analysis

11.1 North America
- 11.1.1 North America Gastrointestinal Drugs Market Overview
- 11.1.2 North America Gastrointestinal Drugs Market - Breakdown, by Key Countries, 2023 and 2031 (%)
  - 11.1.2.1 United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.1.1 United States: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.2.1.2 United States: North America Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.2.1.3 United States: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.2.1.4 United States: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.1.2.2 Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.2.1 Canada: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.2.2.2 Canada: North America Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.2.2.3 Canada: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.2.2.4 Canada: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 11.1.2.3 Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.2.3.1 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 11.1.2.3.2 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Application
    - 11.1.2.3.3 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 11.1.2.3.4 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in North America Gastrointestinal Drugs Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Sanofi SA
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GSK Plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Johnson & Johnson
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bausch Health Companies Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 AstraZeneca Plc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AbbVie Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bayer AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Celltrion Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Pfizer Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms